世界のカスタム抗体市場は、2021年の3億9,300万ドルから2026年までに6億5,200万ドルに達し、予測期間中のCAGRは10.6％と予想されます。特にライフサイエンス業界における研究活動の増加、および、活発化している産学連携がこの市場の主な推進要因です。さらに、カスタム抗体生産の背後にある目的は、特定の定性的または定量的免疫検出法で良好に機能する抗体を取得することです。カタログ抗体の品質（結果の再現性を確保するため）もこの市場で懸念されている分野であり、これが主にエンドユーザーがカスタムメイドの抗体を好む理由です。
大手製薬会社と小規模な新興企業が共に、新しいコロナウイルスによって引き起こされる感染を標的とする治療法とワクチンを開発するために一歩踏み出しました。製薬およびバイオテクノロジー企業、研究センター、および学術研究機関でのワクチン関連の研究活動はエッセンシャルであると考えられており、運用および生産においてほとんど影響を受けていません。研究活動の活発化により、研究資金の有用性とカスタム抗体を含む抗体の需要がいずれも増加すると予想されます。
現在、COVID-19のいくつかのワクチンまたは抗ウイルス薬が承認されているか、開発中であり、患者は現在対症療法として治療を受けています。WHOによると、65のワクチン候補があり、そのうち9つの候補はすでに承認されており、56は開発中です。COVID-19の発生の最前線で、世界中の多くの研究者が、COVID-19を引き起こすウイルスであるSARS-CoV-2のウイルス研究に取り組んでいます。生成された抗体は、ワクチンと治療薬の両方について、標的ウイルスを中和する機能的有効性に関する試験が行われます。
COVID-19ワクチンの開発のために、カスタム抗体サービスの使用が増えています。Thermo Fisher Scientific (米) and Abcam plc (米)などのカスタム抗体サービス市場で事業を行っている企業は、研究施設の一時的な閉鎖により、2020年第1四半期と第2四半期の事業に悪影響を受けました。しかし、ロックダウンが徐々に解除されると、世界中の研究所が再開し始めました。ほとんどのサービスプロバイダーは、COVID-19に関連するさまざまな高品質の研究ツールの提供、SARS-Cov-2の重要な製品を開発するための研究開発資源の再割り当て、SARS-CoV-2 / COVID-19研究に使用される既存の製品に対する需要の増加をサポートするために、サプライチェーンと製造の柔軟性の強化、英国、米国、中国全体で、SARS-CoV-2の診断、医薬品、ワクチンの開発に焦点を当てた議論とコラボレーションの開始など、COVID-19に関与する顧客の重要な作業をサポートするアクションを優先しました。Abcam plc。が発行したH1レポートによると、同社は2020年上半期と比較して2021年上半期には6.7％の成長を遂げました。カスタム製品およびライセンス（CP＆L）の収益は、15.9％の成長を記録しました。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 17)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 23)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 DATA TRIANGULATION
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 29)
4 PREMIUM INSIGHTS (Page No. - 35)
4.1 CUSTOM ANTIBODY MARKET OVERVIEW
4.2 NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2020)
4.3 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2020)
4.4 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 38)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing research activities and funding
5.2.1.2 Quality concerns over catalog antibodies
5.2.1.3 Growing industry-academia collaborations
5.2.1.4 Increasing focus on therapeutic antibodies and extensive pipeline drugs
5.2.2 MARKET RESTRAINTS
5.2.2.1 Cost- and time-intensive antibody development process
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 High growth opportunities in developing countries
5.2.3.2 Increasing demand for personalized medicine in protein therapeutics
5.2.3.3 Increasing focus on biomarker discovery
5.2.4 MARKET CHALLENGES
5.2.4.1 Presence of alternative antibodies
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 DEGREE OF COMPETITION
5.4 TECHNOLOGICAL ANALYSIS
5.4.1 CUSTOM ANTIBODY SERVICES
5.5 PATENT ANALYSIS
5.6 PRICING ANALYSIS
5.7 REGULATORY LANDSCAPE
5.8 IMPACT OF COVID-19 ON THE CUSTOM ANTIBODY MARKET
5.9 VALUE CHAIN ANALYSIS OF THE CUSTOM ANTIBODY MARKET
5.10 KEY INDUSTRY TRENDS
5.10.1 INCREASING FOCUS ON ANTIBODY DRUG CONJUGATE
5.10.2 INCREASING FOCUS ON BIOSPECIFC ANTIBODIES
6 CUSTOM ANTIBODY MARKET, BY SERVICE (Page No. - 52)
6.1 INTRODUCTION
6.2 ANTIBODY DEVELOPMENT
6.2.1 ANTIBODY CHARACTERIZATION
6.2.1.1 Characterization eliminates antibodies with heterogeneities that may hamper research studies
6.2.2 ANTIGEN PREPARATION
6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION
6.3 ANTIBODY PRODUCTION & PURIFICATION
6.3.1 RISING DEMAND FOR HIGH-QUALITY ANTIBODIES TO DRIVE MARKET GROWTH
6.4 ANTIBODY FRAGMENTATION & LABELING
6.4.1 INCREASED RESEARCH ACTIVITIES COUPLED WITH THE NEED FOR SPECIFIC ANTIBODY DETECTION TO DRIVE MARKET GROWTH
7 CUSTOM ANTIBODY MARKET, BY TYPE (Page No. - 60)
7.1 INTRODUCTION
7.2 MONOCLONAL ANTIBODIES
7.2.1 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
7.3 POLYCLONAL ANTIBODIES
7.3.1 POLYCLONAL ANTIBODIES ARE PREFERRED IN PROTEOMICS RESEARCH FOR THE DETECTION OF DENATURED PROTEINS
7.4 RECOMBINANT ANTIBODIES
7.4.1 RESEARCH REPRODUCIBILITY OFFERED BY THESE ANTIBODIES IS DRIVING THEIR DEMAND
7.5 OTHER CUSTOM ANTIBODIES
8 CUSTOM ANTIBODY MARKET, BY SOURCE (Page No. - 66)
8.1 INTRODUCTION
8.2 MICE
8.2.1 MICE ARE THE MOST PREFERRED HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION
8.3 RABBITS
8.3.1 ANTIBODIES DEVELOPED IN RABBITS ELIMINATE THE LIMITATION OF SELF-ANTIGEN RECOGNITION IN HUMANS
8.4 OTHER SOURCES
9 CUSTOM ANTIBODY MARKET, BY RESEARCH AREA (Page No. - 70)
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 USE OF ANTIBODIES HAS INCREASED CONSIDERABLY IN CANCER RESEARCH
9.3 INFECTIOUS DISEASES
9.3.1 ANTIBODIES ARE WIDELY USED IN R&D FOR THE DEVELOPMENT OF VACCINES & THERAPEUTICS AGAINST VARIOUS INFECTIOUS DISEASES
9.4 IMMUNOLOGY
9.4.1 ASSESSMENT OF CELL SURFACE ANTIGENS USING ANTIBODIES FORMS AN IMPORTANT FIELD OF RESEARCH IN IMMUNOLOGY
9.5 NEUROBIOLOGY
9.5.1 NEUROBIOLOGY IS ONE OF THE FASTEST-GROWING SEGMENTS IN TERMS OF RESEARCH BEING UNDERTAKEN UTILIZING ANTIBODIES
9.6 STEM CELLS
9.6.1 AVAILABILITY OF HIGH-QUALITY ANTIBODIES HAS BOOSTED STEM CELL RESEARCH
9.7 CARDIOVASCULAR DISEASE
9.7.1 IDENTIFICATION & CHARACTERIZATION OF CVD BIOMARKERS IS AN IMPORTANT RESEARCH AREA UTILIZING ANTIBODIES
9.8 OTHER RESEARCH AREAS
10 CUSTOM ANTIBODY MARKET, BY END USER (Page No. - 78)
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF CUSTOM ANTIBODIES
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 INCREASE IN DNA SEQUENCING STUDIES AND PROTEOMIC RESEARCH TO DRIVE MARKET GROWTH
10.4 CONTRACT RESEARCH ORGANIZATIONS
10.4.1 CONTRACT RESEARCH ORGANIZATIONS PROVIDE AFFORDABLE OUTLETS FOR COMPANIES AND ACADEMIA TO PURSUE NEW MEDICINES
11 CUSTOM ANTIBODY MARKET, BY REGION (Page No. - 84)
11.1 INTRODUCTION (Page No. - 85)
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Growing research in the field of structure-based drug design and therapeutic mAbs to drive market growth
11.2.2 CANADA
11.2.2.1 Increasing genomic research to drive the adoption of custom antibodies in the coming years
11.3 EUROPE
11.3.1 GERMANY
11.3.1.1 High investments for the development of ADCs support the growth of the custom antibody market in Germany
11.3.2 UK
11.3.2.1 Growing research investments to drive growth in the life science research market
11.3.3 FRANCE
11.3.3.1 Expanding pipeline of therapeutic mAbs along with increasing investments in research are supporting market growth
11.3.4 ITALY
11.3.4.1 Growing proteomics and genomics research at the academic level to play a key role in market growth in Italy
11.3.5 SPAIN
11.3.5.1 Increasing focus on the advancement of translational personalized medicine is expected to drive market growth
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.1.1 Large number of research initiatives toward the development of various ADCs are supporting market growth in Japan
11.4.2 CHINA
11.4.2.1 China is one of the fastest-growing markets in the research sector and is expected to dominate the market in the coming years
11.4.3 INDIA
11.4.3.1 Research for generic mAbs and fusion mAbs as therapeutics is expected to propel the custom antibody market in the country
11.4.4 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 INCREASING APPLICATIONS OF RESEARCH-SPECIFIC CUSTOM ANTIBODIES TO DRIVE MARKET GROWTH IN LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON AFRICA TO DRIVE THE MARKET FOR CUSTOM ANTIBODIES IN THE REGION
12 COMPETITIVE LANDSCAPE (Page No. - 135)
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY MARKET PLAYERS
12.3 MARKET SHARE ANALYSIS
12.4 GROWTH STRATEGIES ADOPTED BY MAJOR AND EMERGING PLAYERS
12.4.1 CUSTOM ANTIBODY MARKET: KEY DEALS (JANUARY 2018 TO APRIL 2021)
12.4.2 CUSTOM ANTIBODY MARKET: KEY EXPANSIONS (JANUARY 2018 TO APRIL 2021)
12.5 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX, 2020
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
13 COMPANY PROFILES (Page No. - 141)
13.1 KEY MARKET PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC, INC.
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 SWOT analysis
13.1.1.4 Recent developments
13.1.1.5 MnM view
13.1.2 GENSCRIPT
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 SWOT analysis
13.1.2.4 Recent developments
13.1.2.5 MnM view
13.1.3 ABCAM PLC
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 SWOT analysis
13.1.3.4 Recent developments
13.1.3.5 MnM view
13.1.4 CELL SIGNALING TECHNOLOGY, INC.
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.3 Recent developments
13.1.5 BIO-RAD LABORATORIES, INC.
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 SWOT analysis
13.1.6 MERCK KGAA
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 SWOT analysis
13.1.6.4 Recent developments
13.1.7 AGILENT TECHNOLOGIES, INC.
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.8 BIOLEGEND, INC.
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.8.3 Recent developments
13.1.9 ROCKLAND IMMUNOCHEMICALS, INC.
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.10 PROMAB BIOTECHNOLOGIES, INC.
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.11 INNOVAGEN AB
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.12 PROTEOGENIX
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.13 BIO-TECHNE
13.1.13.1 Business overview
13.1.13.2 Services offered
13.1.14 CREATIVE DIAGNOSTICS
13.1.14.1 Business overview
13.1.14.2 Services offered
13.1.15 SINO BIOLOGICAL, INC.
13.1.15.1 Business overview
13.1.15.2 Services offered
13.1.16 RAYBIOTECH, INC.
13.1.16.1 Business overview
13.1.16.2 Services offered
13.1.17 ABBIOTEC, INC.
13.1.17.1 Business overview
13.1.17.2 Services offered
13.1.18 PROSCI
13.1.18.1 Business overview
13.1.18.2 Services offered
13.1.19 BOSTER BIOLOGICAL TECHNOLOGY
13.1.19.1 Business overview
13.1.19.2 Services offered
13.1.20 CAPRALOGICS, INC.
13.1.20.1 Business overview
13.1.20.2 Services offered
14 APPENDIX (Page No. - 181)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
LIST OF TABLES (166 Tables)
TABLE 1 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2010-2025 (USD BILLION)
TABLE 3 CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 5 ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 6 ANTIBODY DEVELOPMENT MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 7 ANTIBODY CHARACTERIZATION MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 8 ANTIGEN PREPARATION MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 9 IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 10 ANTIBODY PRODUCTION & PURIFICATION MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 11 ANTIBODY FRAGMENTATION & LABELING MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 12 CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 13 CUSTOM MONOCLONAL ANTIBODIES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 14 CUSTOM POLYCLONAL ANTIBODIES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 15 CUSTOM RECOMBINANT ANTIBODIES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 16 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 17 CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 18 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2019-2026 (USD MILLION)
TABLE 19 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2019-2026 (USD MILLION)
TABLE 20 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2019-2026 (USD MILLION)
TABLE 21 CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 22 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 23 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD MILLION)
TABLE 24 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 25 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 26 CUSTOM ANTIBODY MARKET FOR STEM CELLS, BY REGION, 2019-2026 (USD MILLION)
TABLE 27 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2019-2026 (USD MILLION)
TABLE 28 CUSTOM ANTIBODY MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2019-2026 (USD MILLION)
TABLE 29 CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 30 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 31 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019-2026 (USD MILLION)
TABLE 32 CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019-2026 (USD MILLION)
TABLE 33 CUSTOM ANTIBODY MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 34 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 35 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 36 NORTH AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 37 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 38 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 39 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 40 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 41 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 42 US: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 43 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 44 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 45 US: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 46 US: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 47 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 48 CANADA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 49 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 50 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 51 CANADA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 52 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 53 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 54 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 55 EUROPE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 56 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 57 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 58 EUROPE: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 59 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 60 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 61 GERMANY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 62 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 63 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 64 GERMANY: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 65 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 66 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 67 UK: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 68 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 69 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 70 UK: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 71 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 72 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 73 FRANCE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 74 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 75 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 76 FRANCE: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 77 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 78 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 79 ITALY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 80 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 81 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 82 ITALY: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 83 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 84 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 85 SPAIN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 86 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 87 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 88 SPAIN: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 89 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 90 ROE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 91 ROE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 92 ROE: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 93 ROE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 94 ROE: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 95 ROE: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 97 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 98 ASIA PACIFIC: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 99 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 102 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 103 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 104 JAPAN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 105 JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 106 JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 107 JAPAN: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 108 JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 109 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 110 CHINA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 111 CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 112 CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 113 CHINA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 114 CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 115 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 116 INDIA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 117 INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 118 INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 119 INDIA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 120 INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 121 ROAPAC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 122 ROAPAC: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 123 ROAPAC: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 124 ROAPAC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 125 ROAPAC: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 126 ROAPAC: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 127 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 128 LATIN AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 129 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 130 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 131 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 132 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 133 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019-2026 (USD MILLION)
TABLE 134 MIDDLE EAST & AFRICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019-2026 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019-2026 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2019-2026 (USD MILLION)
TABLE 139 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
TABLE 140 DEALS, JANUARY 2018-MARCH 2021
TABLE 141 GENSCRIPT: BUSINESS OVERVIEW
TABLE 142 DEALS, JANUARY 2018-MARCH 2021
TABLE 143 ABCAM PLC: BUSINESS OVERVIEW
TABLE 144 DEALS, JANUARY 2018-MARCH 2021
TABLE 145 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
TABLE 146 EXPANSIONS, JANUARY 2018-MARCH 2021
TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
TABLE 148 MERCK KGAA.: BUSINESS OVERVIEW
TABLE 149 DEALS, JANUARY 2018-MARCH 2021
TABLE 150 EXPANSIONS, JANUARY 2018-MARCH 2021
TABLE 151 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
TABLE 152 EXPANSIONS, JANUARY 2018-MARCH 2021
TABLE 153 BIOLEGEND, INC.: BUSINESS OVERVIEW
TABLE 154 DEALS, JANUARY 2018-MARCH 2021
TABLE 155 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
TABLE 156 PROMAB BIOTECHNOLOGIES, INC: BUSINESS OVERVIEW
TABLE 157 INNOVAGEN AB: BUSINESS OVERVIEW
TABLE 158 PROTEOGENIX: BUSINESS OVERVIEW
TABLE 159 BIO-TECHNE: BUSINESS OVERVIEW
TABLE 160 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
TABLE 161 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
TABLE 162 RAYBIOTECH, INC.: BUSINESS OVERVIEW
TABLE 163 ABBIOTEC, INC.: BUSINESS OVERVIEW
TABLE 164 PROSCI: BUSINESS OVERVIEW
TABLE 165 BOSTER BIOLOGICAL TECHNOLOGY: BUSINESS OVERVIEW
TABLE 166 CAPRALOGICS, INC.: BUSINESS OVERVIEW
LIST OF FIGURES (29 Figures)
FIGURE 1 BREAKDOWN OF PRIMARIES: CUSTOM ANTIBODY MARKET
FIGURE 2 DATA TRIANGULATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE-BASED ESTIMATION)
FIGURE 4 CUSTOM ANTIBODY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2020
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 6 CUSTOM ANTIBODY MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 CUSTOM ANTIBODY MARKET SHARE, BY SERVICE, 2020 VS. 2026
FIGURE 8 CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2020
FIGURE 9 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2021 VS. 2026
FIGURE 10 CUSTOM ANTIBODY MARKET SHARE, BY RESEARCH AREA, 2020
FIGURE 11 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2020
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE CUSTOM ANTIBODY MARKET
FIGURE 13 QUALITY CONCERNS OVER CATALOG ANTIBODIES TO DRIVE MARKET GROWTH
FIGURE 14 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CUSTOM ANTIBODY MARKET IN 2020
FIGURE 15 MICE ARE THE LARGEST SOURCE OF CUSTOM ANTIBODIES
FIGURE 16 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CUSTOM ANTIBODY MARKET FROM 2021 TO 2026
FIGURE 17 NUMBER OF PATENTS GRANTED FOR CUSTOM ANTIBODIES, JANUARY 2010-DECEMBER 2020
FIGURE 18 CUSTOM ANTIBODY MARKET: GEOGRAPHIC SNAPSHOT (2021)
FIGURE 19 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT
FIGURE 20 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT
FIGURE 21 CUSTOM ANTIBODY MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
FIGURE 22 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX, 2020
FIGURE 23 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
FIGURE 24 GENSCRIPT: COMPANY SNAPSHOT (2019)
FIGURE 25 ABCAM PLC: COMPANY SNAPSHOT (2020)
FIGURE 26 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
FIGURE 27 MERCK KGAA.: COMPANY SNAPSHOT (2020)
FIGURE 28 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
FIGURE 29 BIO-TECHNE: COMPANY SNAPSHOT (2020)
